CSL Completes Transaction to Acquire a Majority Stake in Chinese Plasma Fractionator
CSL Limited today announced that it has closed a joint venture transaction with Humanwell Healthcare Group Co. Ltd. to acquire a majority stake in plasma-derived therapies manufacturer Wuhan Zhong Yuan Rui De Biological Products Co. Ltd.

CSL Response to Patent Infringement Complaint
ASX Announcement

CSL Limited has become aware that Bioverativ has filed complaints in the U.S. District Court for the District of Delaware and with the International Trade Commission.


HAEGARDA® (C1 Esterase Inhibitor Subcutaneous [Human]) FDA Approval
ASX Announcement CSL today announced that the U.S. Food and Drug Administration (FDA) has approved CSL Behring’s HAEGARDA® (C1 Esterase Inhibitor Subcutaneous [Human]), the only subcutaneous therapy indicated for routine prophylaxis to prevent hereditary angioedema (HAE) attacks in adolescent and adult patients.

All News Releases >

Media Resources

CSL Behring Company Information
CSL Company Information >
CSL Behring Media Contacts
CSL Media
Contacts >
CSL Behring Social Media
CSL Social
Media >
CSL Behring MultiMedia Library
CSL Media
Library >

© 2017 CSL Limited